Plus Therapeutics Inc Cash Flow Conversion Efficiency
Plus Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Plus Therapeutics Inc (PSTV) has a cash flow conversion efficiency ratio of -1.306x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.13 Million) by net assets ($5.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Plus Therapeutics Inc (1998–2025)
Cash flow conversion efficiency of Plus Therapeutics Inc from 1998 to 2025. This chart illustrates how Plus Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PSTV share price today for real-time trading data and today's change.
Plus Therapeutics Inc Cash Flow Conversion Ratio Explained
Plus Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Plus Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Plus Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Plus Therapeutics Inc (PSTV) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Andalan Sakti Primaindo PT
JK:ASPI
|
-0.124x |
|
Daewon Co. Ltd
KQ:007680
|
-0.015x |
|
TT Vision Holdings Berhad
KLSE:0272
|
-0.018x |
|
Santa Fe Minerals Ltd
AU:SFM
|
0.000x |
|
Alpha Holdings Inc
KQ:117670
|
-0.065x |
|
Ktop Reit
KO:145270
|
0.014x |
|
Italian-Thai Development Public Company Limited
F:NYVF
|
0.490x |
|
WiseChip Semiconductor
TWO:5245
|
0.033x |
Annual Cash Flow Conversion Efficiency for Plus Therapeutics Inc (1998–2025)
The table below shows the annual cash flow conversion efficiency of Plus Therapeutics Inc from 1998 to 2025. Review Plus Therapeutics Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.00 Million | $-20.77 Million | -5.199x | -540.83% |
| 2024-12-31 | $-8.95 Million | $-10.55 Million | 1.179x | -87.63% |
| 2023-12-31 | $-1.35 Million | $-12.85 Million | 9.533x | +573.66% |
| 2022-12-31 | $6.45 Million | $-12.97 Million | -2.013x | -112.16% |
| 2021-12-31 | $10.84 Million | $-10.28 Million | -0.949x | +65.91% |
| 2020-12-31 | $3.03 Million | $-8.43 Million | -2.783x | +45.35% |
| 2019-12-31 | $1.16 Million | $-5.91 Million | -5.091x | -122.15% |
| 2018-12-31 | $5.22 Million | $-11.97 Million | -2.292x | -64.35% |
| 2017-12-31 | $13.00 Million | $-18.13 Million | -1.394x | +21.57% |
| 2016-12-31 | $10.99 Million | $-19.53 Million | -1.778x | -6.03% |
| 2015-12-31 | $12.21 Million | $-20.47 Million | -1.677x | -131.53% |
| 2014-12-31 | $-5.70 Million | $-30.33 Million | 5.319x | +148.20% |
| 2013-12-31 | $3.13 Million | $-34.56 Million | -11.035x | -121.27% |
| 2012-12-31 | $6.46 Million | $-32.19 Million | -4.987x | -40.43% |
| 2011-12-31 | $9.95 Million | $-35.32 Million | -3.551x | -244.59% |
| 2010-12-31 | $22.87 Million | $-23.57 Million | -1.031x | -115.84% |
| 2009-12-31 | $-3.66 Million | $-23.81 Million | 6.508x | +50.42% |
| 2008-12-31 | $-7.72 Million | $-33.39 Million | 4.327x | +35.59% |
| 2007-12-31 | $-9.40 Million | $-30.00 Million | 3.191x | +109.33% |
| 2006-12-31 | $-10.81 Million | $-16.48 Million | 1.524x | +762.42% |
| 2005-12-31 | $-6.23 Million | $-1.10 Million | 0.177x | +118.04% |
| 2004-12-31 | $12.83 Million | $-12.57 Million | -0.980x | -101.63% |
| 2003-12-31 | $14.91 Million | $-7.25 Million | -0.486x | -83.45% |
| 2002-12-31 | $26.00 Million | $-6.89 Million | -0.265x | -22.50% |
| 2001-12-31 | $38.49 Million | $-8.32 Million | -0.216x | -257.74% |
| 2000-12-31 | $49.34 Million | $-2.98 Million | -0.060x | -107.28% |
| 1999-12-31 | $-6.15 Million | $-5.11 Million | 0.831x | +105.89% |
| 1998-12-31 | $108.00K | $-1.52 Million | -14.102x | -- |
About Plus Therapeutics Inc
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric br… Read more